Ricevi le ultime notizie sulle azioni Synlogic con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di SYBX

Ultime notizie per

Synlogic

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

Synlogic Inc

Earnings

Press Releases

Synlogic Reports Third Quarter 2024 Financial Results

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

ABBV

AVIR

CARM

COYA

MEIP

RIBT

SYBX

TSX:PHO

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Aptevo Therapeutics

BriaCell Therapeutics Corp. - Common Shares

BriaCell Therapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Curis

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

enGene Holdings

Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech

FibroBiologics

Geovax Labs

Immuron Limited - American Depositary Shares

Immuron

Longeveron

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Lunai Bioworks

Lisata Therapeutics

Moleculin Biotech

OSR Holdings

Passage Bio

BiomX

ProMIS Neurosciences Inc. - Common Shares

ProMIS Neurosciences

Propanc Biopharma

Tharimmune

XOMA Royalty Corporation - 8.625% Series A Cumulative Perpetual Preferred Stock

Comments

Synlogic Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO